LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 13

Search options

  1. Article ; Online: A catalogue of somatic NRF2 gain-of-function mutations in cancer.

    Kerins, Michael John / Ooi, Aikseng

    Scientific reports

    2018  Volume 8, Issue 1, Page(s) 12846

    Abstract: Identification and characterization of somatic mutations in cancer have important prognostication and treatment implications. Genes encoding the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor and its negative regulator, Kelch- ... ...

    Abstract Identification and characterization of somatic mutations in cancer have important prognostication and treatment implications. Genes encoding the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor and its negative regulator, Kelch-like ECH-associated protein 1 (KEAP1), are frequently mutated in cancer. These mutations drive constitutive NRF2 activation and correlate with poor prognosis. Despite its apparent significance, a comprehensive catalogue of somatic NRF2 mutations across different tumor types is still lacking. Here, we catalogue NRF2 mutations in The Cancer Genome Atlas (TCGA) database. 226 unique NRF2-mutant tumors were identified from 10,364 cases. NRF2 mutations were found in 21 out of the 33 tumor types. A total of 11 hotspots were identified. Of these, mutation to the R34 position was most frequent. Notably, R34 and D29 mutations were overrepresented in bladder, lung, and uterine cancers. Analyses of corresponding RNA sequencing data using a de novo derived gene expression classifier showed that the R34 mutations drive constitutive NRF2 activation with a selection pressure biased against the formation of R34L. Of all R34 mutants, R34L conferred the least degree of protein stabilization, suggesting a pro-tumor NRF2 half-life threshold. Our findings offer a comprehensive catalogue of NRF2 mutations in cancer that can help prognostication and NRF2 research.
    MeSH term(s) Amino Acid Substitution ; Cell Line, Tumor ; Computational Biology/methods ; Databases, Genetic ; Gain of Function Mutation ; Humans ; Kelch-Like ECH-Associated Protein 1/genetics ; Kelch-Like ECH-Associated Protein 1/metabolism ; NF-E2-Related Factor 2/genetics ; NF-E2-Related Factor 2/metabolism ; Neoplasms/genetics ; Neoplasms/metabolism ; Protein Stability ; Sequence Analysis, DNA ; Signal Transduction
    Chemical Substances KEAP1 protein, human ; Kelch-Like ECH-Associated Protein 1 ; NF-E2-Related Factor 2 ; NFE2L2 protein, human
    Language English
    Publishing date 2018-08-27
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-018-31281-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The Roles of NRF2 in Modulating Cellular Iron Homeostasis.

    Kerins, Michael John / Ooi, Aikseng

    Antioxidants & redox signaling

    2017  Volume 29, Issue 17, Page(s) 1756–1773

    Abstract: Significance: Iron and oxygen are intimately linked: iron is an essential nutrient utilized as a cofactor in enzymes for oxygen transport, oxidative phosphorylation, and metabolite oxidation. However, excess labile iron facilitates the formation of ... ...

    Abstract Significance: Iron and oxygen are intimately linked: iron is an essential nutrient utilized as a cofactor in enzymes for oxygen transport, oxidative phosphorylation, and metabolite oxidation. However, excess labile iron facilitates the formation of oxygen-derived free radicals capable of damaging biomolecules. Therefore, biological utilization of iron is a tightly regulated process. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor, which can respond to oxidative and electrophilic stress, regulates several genes involved in iron metabolism. Recent Advances: The bulk of NRF2 transcription factor research has focused on its roles in detoxification and cancer prevention. Recent works have identified that several genes involved in heme synthesis, hemoglobin catabolism, iron storage, and iron export are under the control of NRF2. Constitutive NRF2 activation and subsequent deregulation of iron metabolism have been implicated in cancer development: NRF2-mediated upregulation of the iron storage protein ferritin or heme oxygenase 1 can lead to enhanced proliferation and therapy resistance. Of note, NRF2 activation and alterations to iron signaling in cancers may hinder efforts to induce the iron-dependent cell death process known as ferroptosis.
    Critical issues: Despite growing recognition of NRF2 as a modulator of iron signaling, exactly how iron metabolism is altered due to NRF2 activation in normal physiology and in pathologic conditions remains imprecise; moreover, the roles of NRF2-mediated iron signaling changes in disease progression are only beginning to be uncovered.
    Future directions: Further studies are necessary to connect NRF2 activation with physiological and pathological changes to iron signaling and oxidative stress. Antioxid. Redox Signal. 00, 000-000.
    MeSH term(s) Animals ; Homeostasis ; Humans ; Iron/metabolism ; NF-E2-Related Factor 2/metabolism ; Neoplasms/metabolism ; Oxidative Stress ; Signal Transduction
    Chemical Substances NF-E2-Related Factor 2 ; Iron (E1UOL152H7)
    Language English
    Publishing date 2017-09-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Review
    ZDB-ID 1483836-9
    ISSN 1557-7716 ; 1523-0864
    ISSN (online) 1557-7716
    ISSN 1523-0864
    DOI 10.1089/ars.2017.7176
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A catalogue of somatic NRF2 gain-of-function mutations in cancer

    Michael John Kerins / Aikseng Ooi

    Scientific Reports, Vol 8, Iss 1, Pp 1-

    2018  Volume 13

    Abstract: Abstract Identification and characterization of somatic mutations in cancer have important prognostication and treatment implications. Genes encoding the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor and its negative regulator, ... ...

    Abstract Abstract Identification and characterization of somatic mutations in cancer have important prognostication and treatment implications. Genes encoding the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor and its negative regulator, Kelch-like ECH-associated protein 1 (KEAP1), are frequently mutated in cancer. These mutations drive constitutive NRF2 activation and correlate with poor prognosis. Despite its apparent significance, a comprehensive catalogue of somatic NRF2 mutations across different tumor types is still lacking. Here, we catalogue NRF2 mutations in The Cancer Genome Atlas (TCGA) database. 226 unique NRF2-mutant tumors were identified from 10,364 cases. NRF2 mutations were found in 21 out of the 33 tumor types. A total of 11 hotspots were identified. Of these, mutation to the R34 position was most frequent. Notably, R34 and D29 mutations were overrepresented in bladder, lung, and uterine cancers. Analyses of corresponding RNA sequencing data using a de novo derived gene expression classifier showed that the R34 mutations drive constitutive NRF2 activation with a selection pressure biased against the formation of R34L. Of all R34 mutants, R34L conferred the least degree of protein stabilization, suggesting a pro-tumor NRF2 half-life threshold. Our findings offer a comprehensive catalogue of NRF2 mutations in cancer that can help prognostication and NRF2 research.
    Keywords Medicine ; R ; Science ; Q
    Language English
    Publishing date 2018-08-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction.

    Kerins, Michael J / Milligan, John / Wohlschlegel, James A / Ooi, Aikseng

    Cancer science

    2018  Volume 109, Issue 9, Page(s) 2757–2766

    Abstract: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome characterized by inactivation of the Krebs cycle enzyme fumarate hydratase (FH). HLRCC patients are at high risk of developing kidney cancer of type 2 papillary ... ...

    Abstract Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome characterized by inactivation of the Krebs cycle enzyme fumarate hydratase (FH). HLRCC patients are at high risk of developing kidney cancer of type 2 papillary morphology that is refractory to current radiotherapy, immunotherapy and chemotherapy. Hence, an effective therapy for this deadly form of cancer is urgently needed. Here, we show that FH inactivation (FH
    MeSH term(s) Cell Line, Tumor ; Enzyme Activation ; Fumarate Hydratase/physiology ; Glutathione Peroxidase/physiology ; Humans ; Leiomyomatosis/enzymology ; Leiomyomatosis/pathology ; Neoplastic Syndromes, Hereditary/enzymology ; Neoplastic Syndromes, Hereditary/pathology ; Phospholipid Hydroperoxide Glutathione Peroxidase ; Reactive Oxygen Species/metabolism ; Skin Neoplasms/enzymology ; Skin Neoplasms/pathology ; Uterine Neoplasms/enzymology ; Uterine Neoplasms/pathology
    Chemical Substances Reactive Oxygen Species ; Phospholipid Hydroperoxide Glutathione Peroxidase (EC 1.11.1.12) ; Glutathione Peroxidase (EC 1.11.1.9) ; Fumarate Hydratase (EC 4.2.1.2)
    Language English
    Publishing date 2018-07-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 2115647-5
    ISSN 1349-7006 ; 1349-7006
    ISSN (online) 1349-7006
    ISSN 1349-7006
    DOI 10.1111/cas.13701
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Iron control of erythroid microtubule cytoskeleton as a potential target in treatment of iron-restricted anemia.

    Goldfarb, Adam N / Freeman, Katie C / Sahu, Ranjit K / Elagib, Kamaleldin E / Holy, Maja / Arneja, Abhinav / Polanowska-Grabowska, Renata / Gru, Alejandro A / White, Zollie / Khalil, Shadi / Kerins, Michael J / Ooi, Aikseng / Leitinger, Norbert / Luckey, Chance John / Delehanty, Lorrie L

    Nature communications

    2021  Volume 12, Issue 1, Page(s) 1645

    Abstract: Anemias of chronic disease and inflammation (ACDI) result from restricted iron delivery to erythroid progenitors. The current studies reveal an organellar response in erythroid iron restriction consisting of disassembly of the microtubule cytoskeleton ... ...

    Abstract Anemias of chronic disease and inflammation (ACDI) result from restricted iron delivery to erythroid progenitors. The current studies reveal an organellar response in erythroid iron restriction consisting of disassembly of the microtubule cytoskeleton and associated Golgi disruption. Isocitrate supplementation, known to abrogate the erythroid iron restriction response, induces reassembly of microtubules and Golgi in iron deprived progenitors. Ferritin, based on proteomic profiles, regulation by iron and isocitrate, and putative interaction with microtubules, is assessed as a candidate mediator. Knockdown of ferritin heavy chain (FTH1) in iron replete progenitors induces microtubule collapse and erythropoietic blockade; conversely, enforced ferritin expression rescues erythroid differentiation under conditions of iron restriction. Fumarate, a known ferritin inducer, synergizes with isocitrate in reversing molecular and cellular defects of iron restriction and in oral remediation of murine anemia. These findings identify a cytoskeletal component of erythroid iron restriction and demonstrate potential for its therapeutic targeting in ACDI.
    MeSH term(s) Anemia/metabolism ; Anemia/therapy ; Animals ; Cell Proliferation ; Cytoskeleton/metabolism ; Disease Models, Animal ; Erythroid Cells/metabolism ; Erythropoiesis/physiology ; Female ; Ferritins/metabolism ; Iron/metabolism ; Isocitrates ; Male ; Mice ; Mice, Inbred C57BL ; Microtubules/metabolism ; Oxidoreductases/metabolism ; Proteomics
    Chemical Substances Isocitrates ; Ferritins (9007-73-2) ; isocitric acid (9RW6G5D4MQ) ; Iron (E1UOL152H7) ; Fth1 protein, mouse (EC 1.-) ; Oxidoreductases (EC 1.-)
    Language English
    Publishing date 2021-03-12
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-021-21938-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes.

    Kerins, Michael John / Vashisht, Ajay Amar / Liang, Benjamin Xi-Tong / Duckworth, Spencer Jordan / Praslicka, Brandon John / Wohlschlegel, James Akira / Ooi, Aikseng

    Molecular and cellular biology

    2017  Volume 37, Issue 11

    Abstract: Germ line mutations of the gene encoding the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase ( ...

    Abstract Germ line mutations of the gene encoding the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (
    MeSH term(s) Amino Acid Sequence ; Carcinoma, Renal Cell/enzymology ; Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Ferritins/genetics ; Forkhead Box Protein M1/metabolism ; Fumarate Hydratase/metabolism ; Fumarates/pharmacology ; Humans ; Intracellular Space/metabolism ; Iron Regulatory Protein 2/chemistry ; Iron Regulatory Protein 2/metabolism ; Kidney Neoplasms/enzymology ; Kidney Neoplasms/genetics ; Kidney Neoplasms/pathology ; Leiomyomatosis/enzymology ; Leiomyomatosis/genetics ; Leiomyomatosis/pathology ; Models, Biological ; NF-E2-Related Factor 2/metabolism ; Protein Biosynthesis/drug effects ; Signal Transduction/drug effects ; Succinic Acid/metabolism ; Transcription, Genetic/drug effects
    Chemical Substances FOXM1 protein, human ; Forkhead Box Protein M1 ; Fumarates ; NF-E2-Related Factor 2 ; NFE2L2 protein, human ; Ferritins (9007-73-2) ; Succinic Acid (AB6MNQ6J6L) ; Fumarate Hydratase (EC 4.2.1.2) ; IREB2 protein, human (EC 4.2.1.3) ; Iron Regulatory Protein 2 (EC 4.2.1.3)
    Language English
    Publishing date 2017-05-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 779397-2
    ISSN 1098-5549 ; 0270-7306
    ISSN (online) 1098-5549
    ISSN 0270-7306
    DOI 10.1128/MCB.00079-17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes

    Kerins, Michael John / Vashisht, Ajay Amar / Liang, Benjamin Xi-Tong / Duckworth, Spencer Jordan / Praslicka, Brandon John / Wohlschlegel, James Akira / Ooi, Aikseng

    Molecular and Cellular Biology. 2017 June 1, v. 37, no. 11 p.e00079-17-

    2017  

    Abstract: Germ line mutations of the gene encoding the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) cause a hereditary cancer syndrome known as hereditary leiomyomatosis and renal cell cancer (HLRCC). HLRCC-associated tumors harbor biallelic FH ... ...

    Abstract Germ line mutations of the gene encoding the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) cause a hereditary cancer syndrome known as hereditary leiomyomatosis and renal cell cancer (HLRCC). HLRCC-associated tumors harbor biallelic FH inactivation that results in the accumulation of the TCA cycle metabolite fumarate. Although it is known that fumarate accumulation can alter cellular signaling, if and how fumarate confers a growth advantage remain unclear. Here we show that fumarate accumulation confers a chronic proliferative signal by disrupting cellular iron signaling. Specifically, fumarate covalently modifies cysteine residues on iron regulatory protein 2 (IRP2), rendering it unable to repress ferritin mRNA translation. Simultaneously, fumarate increases ferritin gene transcription by activating the NRF2 (nuclear factor [erythroid-derived 2]-like 2) transcription factor. In turn, increased ferritin protein levels promote the expression of the promitotic transcription factor FOXM1 (Forkhead box protein M1). Consistently, clinical HLRCC tissues showed increased expression levels of both FOXM1 and its proliferation-associated target genes. This finding demonstrates how FH inactivation can endow cells with a growth advantage.
    Keywords chemical bonding ; cysteine ; ferritin ; fumarate hydratase ; fumarates ; genes ; germ cells ; metabolites ; regulatory proteins ; renal cell carcinoma ; transcription (genetics) ; transcription factors ; tricarboxylic acid cycle ; FH ; FOXM1 ; fumarate ; HLRCC ; NRF2
    Language English
    Dates of publication 2017-0601
    Publishing place Taylor & Francis
    Document type Article ; Online
    ZDB-ID 779397-2
    ISSN 1098-5549 ; 0270-7306
    ISSN (online) 1098-5549
    ISSN 0270-7306
    DOI 10.1128/MCB.00079-17
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  8. Article ; Online: Iron control of erythroid microtubule cytoskeleton as a potential target in treatment of iron-restricted anemia

    Adam N. Goldfarb / Katie C. Freeman / Ranjit K. Sahu / Kamaleldin E. Elagib / Maja Holy / Abhinav Arneja / Renata Polanowska-Grabowska / Alejandro A. Gru / Zollie White / Shadi Khalil / Michael J. Kerins / Aikseng Ooi / Norbert Leitinger / Chance John Luckey / Lorrie L. Delehanty

    Nature Communications, Vol 12, Iss 1, Pp 1-

    2021  Volume 14

    Abstract: Debilitating anemias in chronic diseases can result from deficient iron delivery to red cell precursors. Here, the authors show how this deficiency damages the cytoskeletal framework of progenitor cells and identify a targeted strategy for cytoskeletal ... ...

    Abstract Debilitating anemias in chronic diseases can result from deficient iron delivery to red cell precursors. Here, the authors show how this deficiency damages the cytoskeletal framework of progenitor cells and identify a targeted strategy for cytoskeletal repair, leading to anemia correction.
    Keywords Science ; Q
    Language English
    Publishing date 2021-03-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?

    Ledwidge, Mark T / Ryan, Fiona / Kerins, David M / O'Connell, Damian / Cefali, Gene / Harmon, Shona / Jones, Michael / Gilmer, John F

    Atherosclerosis

    2012  Volume 221, Issue 2, Page(s) 478–483

    Abstract: Objectives: To evaluate the pharmacokinetics and effects of the first immediate-release (IR) niacin-aspirin prodrug (ST0702) on lipid, prostaglandin and thromboxane levels in non-human primates (NHPs).: Methods: We compared 28 mg/kg crystalline IR ... ...

    Abstract Objectives: To evaluate the pharmacokinetics and effects of the first immediate-release (IR) niacin-aspirin prodrug (ST0702) on lipid, prostaglandin and thromboxane levels in non-human primates (NHPs).
    Methods: We compared 28 mg/kg crystalline IR niacin, equimolar doses of crystalline IR ST0702 and control on low density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB) and triglycerides (Tg) in NHPs (6 per group) over 48 h (daily oral gavage). In addition, we compared IR niacin and ST0702 effects on prostaglandin (PG)D(2), ex vivo thromboxane B(2) (TXB(2)) levels and plasma pharmacokinetics.
    Results: ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model. ST0702 resulted in 38% and 40% reductions in LDL-C and ApoB levels compared to control over the 48 h period (p = 0.027 and p = 0.012 respectively). Corresponding values were 32% and 25% for niacin (both p = NS vs control). ST0702, but not niacin, decreased Tg levels (p = 0.017 for between group difference). Post prandial glycaemia was attenuated vs baseline in the ST0702 group only. Ex vivo serum TXB(2) generation was suppressed at 15 min and complete suppression of TXB(2) was sustained at 24h (p<0.01 vs niacin). ST0702 suppressed PGD(2) exposure eightfold (p = 0.012) compared to niacin over the first 24h.
    Conclusions: This two-dose study in NHPs suggests that ST0702 is more effective than IR niacin on lipid profiles, while suppressing TXB(2) and PGD(2) increases and prevents post-prandial glycaemia. ST0702 shows promise as a new IR therapeutic option for niacin.
    MeSH term(s) Animals ; Apolipoproteins B/blood ; Aspirin/analogs & derivatives ; Aspirin/blood ; Aspirin/pharmacokinetics ; Aspirin/pharmacology ; Blood Glucose/drug effects ; Chemistry, Pharmaceutical ; Cholesterol, LDL/blood ; Cyclooxygenase Inhibitors/blood ; Cyclooxygenase Inhibitors/pharmacokinetics ; Cyclooxygenase Inhibitors/pharmacology ; Hyperglycemia/blood ; Hyperglycemia/prevention & control ; Hypolipidemic Agents/blood ; Hypolipidemic Agents/pharmacokinetics ; Hypolipidemic Agents/pharmacology ; Isosorbide/analogs & derivatives ; Isosorbide/blood ; Isosorbide/pharmacokinetics ; Isosorbide/pharmacology ; Lipid Metabolism/drug effects ; Lipids/blood ; Macaca fascicularis ; Models, Biological ; Niacin/analogs & derivatives ; Niacin/blood ; Niacin/pharmacokinetics ; Niacin/pharmacology ; Postprandial Period ; Prodrugs/pharmacokinetics ; Prodrugs/pharmacology ; Prostaglandin D2/blood ; Salicylates/blood ; Salicylates/pharmacokinetics ; Salicylates/pharmacology ; Thromboxane B2/blood ; Triglycerides/blood
    Chemical Substances Apolipoproteins B ; Blood Glucose ; Cholesterol, LDL ; Cyclooxygenase Inhibitors ; Hypolipidemic Agents ; Lipids ; Prodrugs ; Salicylates ; Triglycerides ; isosorbide-5-nicotinate-2-aspirinate ; Niacin (2679MF687A) ; Thromboxane B2 (54397-85-2) ; Aspirin (R16CO5Y76E) ; Prostaglandin D2 (RXY07S6CZ2) ; Isosorbide (WXR179L51S)
    Language English
    Publishing date 2012-04
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 80061-2
    ISSN 1879-1484 ; 0021-9150
    ISSN (online) 1879-1484
    ISSN 0021-9150
    DOI 10.1016/j.atherosclerosis.2012.01.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

    Wannan, Cassandra M J / Nelson, Barnaby / Addington, Jean / Allott, Kelly / Anticevic, Alan / Arango, Celso / Baker, Justin T / Bearden, Carrie E / Billah, Tashrif / Bouix, Sylvain / Broome, Matthew R / Buccilli, Kate / Cadenhead, Kristin S / Calkins, Monica E / Cannon, Tyrone D / Cecci, Guillermo / Chen, Eric Yu Hai / Cho, Kang Ik K / Choi, Jimmy /
    Clark, Scott R / Coleman, Michael J / Conus, Philippe / Corcoran, Cheryl M / Cornblatt, Barbara A / Diaz-Caneja, Covadonga M / Dwyer, Dominic / Ebdrup, Bjørn H / Ellman, Lauren M / Fusar-Poli, Paolo / Galindo, Liliana / Gaspar, Pablo A / Gerber, Carla / Glenthøj, Louise Birkedal / Glynn, Robert / Harms, Michael P / Horton, Leslie E / Kahn, René S / Kambeitz, Joseph / Kambeitz-Ilankovic, Lana / Kane, John M / Kapur, Tina / Keshavan, Matcheri S / Kim, Sung-Wan / Koutsouleris, Nikolaos / Kubicki, Marek / Kwon, Jun Soo / Langbein, Kerstin / Lewandowski, Kathryn E / Light, Gregory A / Mamah, Daniel / Marcy, Patricia J / Mathalon, Daniel H / McGorry, Patrick D / Mittal, Vijay A / Nordentoft, Merete / Nunez, Angela / Pasternak, Ofer / Pearlson, Godfrey D / Perez, Jesus / Perkins, Diana O / Powers, Albert R / Roalf, David R / Sabb, Fred W / Schiffman, Jason / Shah, Jai L / Smesny, Stefan / Spark, Jessica / Stone, William S / Strauss, Gregory P / Tamayo, Zailyn / Torous, John / Upthegrove, Rachel / Vangel, Mark / Verma, Swapna / Wang, Jijun / Rossum, Inge Winter-van / Wolf, Daniel H / Wolff, Phillip / Wood, Stephen J / Yung, Alison R / Agurto, Carla / Alvarez-Jimenez, Mario / Amminger, Paul / Armando, Marco / Asgari-Targhi, Ameneh / Cahill, John / Carrión, Ricardo E / Castro, Eduardo / Cetin-Karayumak, Suheyla / Mallar Chakravarty, M / Cho, Youngsun T / Cotter, David / D'Alfonso, Simon / Ennis, Michaela / Fadnavis, Shreyas / Fonteneau, Clara / Gao, Caroline / Gupta, Tina / Gur, Raquel E / Gur, Ruben C / Hamilton, Holly K / Hoftman, Gil D / Jacobs, Grace R / Jarcho, Johanna / Ji, Jie Lisa / Kohler, Christian G / Lalousis, Paris Alexandros / Lavoie, Suzie / Lepage, Martin / Liebenthal, Einat / Mervis, Josh / Murty, Vishnu / Nicholas, Spero C / Ning, Lipeng / Penzel, Nora / Poldrack, Russell / Polosecki, Pablo / Pratt, Danielle N / Rabin, Rachel / Rahimi Eichi, Habiballah / Rathi, Yogesh / Reichenberg, Avraham / Reinen, Jenna / Rogers, Jack / Ruiz-Yu, Bernalyn / Scott, Isabelle / Seitz-Holland, Johanna / Srihari, Vinod H / Srivastava, Agrima / Thompson, Andrew / Turetsky, Bruce I / Walsh, Barbara C / Whitford, Thomas / Wigman, Johanna T W / Yao, Beier / Yuen, Hok Pan / Ahmed, Uzair / Byun, Andrew Jin Soo / Chung, Yoonho / Do, Kim / Hendricks, Larry / Huynh, Kevin / Jeffries, Clark / Lane, Erlend / Langholm, Carsten / Lin, Eric / Mantua, Valentina / Santorelli, Gennarina / Ruparel, Kosha / Zoupou, Eirini / Adasme, Tatiana / Addamo, Lauren / Adery, Laura / Ali, Munaza / Auther, Andrea / Aversa, Samantha / Baek, Seon-Hwa / Bates, Kelly / Bathery, Alyssa / Bayer, Johanna M M / Beedham, Rebecca / Bilgrami, Zarina / Birch, Sonia / Bonoldi, Ilaria / Borders, Owen / Borgatti, Renato / Brown, Lisa / Bruna, Alejandro / Carrington, Holly / Castillo-Passi, Rolando I / Chen, Justine / Cheng, Nicholas / Ching, Ann Ee / Clifford, Chloe / Colton, Beau-Luke / Contreras, Pamela / Corral, Sebastián / Damiani, Stefano / Done, Monica / Estradé, Andrés / Etuka, Brandon Asika / Formica, Melanie / Furlan, Rachel / Geljic, Mia / Germano, Carmela / Getachew, Ruth / Goncalves, Mathias / Haidar, Anastasia / Hartmann, Jessica / Jo, Anna / John, Omar / Kerins, Sarah / Kerr, Melissa / Kesselring, Irena / Kim, Honey / Kim, Nicholas / Kinney, Kyle / Krcmar, Marija / Kotler, Elana / Lafanechere, Melanie / Lee, Clarice / Llerena, Joshua / Markiewicz, Christopher / Matnejl, Priya / Maturana, Alejandro / Mavambu, Aissata / Mayol-Troncoso, Rocío / McDonnell, Amelia / McGowan, Alessia / McLaughlin, Danielle / McIlhenny, Rebecca / McQueen, Brittany / Mebrahtu, Yohannes / Mensi, Martina / Hui, Christy Lai Ming / Suen, Yi Nam / Wong, Stephanie Ming Yin / Morrell, Neal / Omar, Mariam / Partridge, Alice / Phassouliotis, Christina / Pichiecchio, Anna / Politi, Pierluigi / Porter, Christian / Provenzani, Umberto / Prunier, Nicholas / Raj, Jasmine / Ray, Susan / Rayner, Victoria / Reyes, Manuel / Reynolds, Kate / Rush, Sage / Salinas, Cesar / Shetty, Jashmina / Snowball, Callum / Tod, Sophie / Turra-Fariña, Gabriel / Valle, Daniela / Veale, Simone / Whitson, Sarah / Wickham, Alana / Youn, Sarah / Zamorano, Francisco / Zavaglia, Elissa / Zinberg, Jamie / Woods, Scott W / Shenton, Martha E

    Schizophrenia bulletin

    2024  

    Abstract: This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of ... ...

    Abstract This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.
    Language English
    Publishing date 2024-03-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 439173-1
    ISSN 1745-1701 ; 0586-7614
    ISSN (online) 1745-1701
    ISSN 0586-7614
    DOI 10.1093/schbul/sbae011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top